Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Salicylic acid & warts

This article was originally published in The Tan Sheet

Executive Summary

"Simple topical treatments containing salicylic acid seem to be both effective and safe" in treating cutaneous warts, according to systematic review of randomized trials reported in Aug. 31 British Medical Journal. Sam Gibbs, Ipswich Hospital, et al., found 13 trials that assessed wart treatment with topical salicylic acid in doses ranging from 15% to 60%. Pooled data from six of these trials showed a cure rate of 75% (144 of 191 cases) compared with 48% in control groups. "No clear evidence was found that any of the other treatments have a particular advantage of either higher cure rates or fewer adverse effects," researchers say. Gibbs et al. conducted computer searches on Medline, Embase, Cochrane and found 50 trials on various wart treatments, although they note the studies were generally of low quality...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel